@prefix : <http://www.transceleratebiopharmainc.com/LY246708/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix bc: <http://www.assero.co.uk/BiomedicalConcept#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/LY246708/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#d6609ada-cb55-4268-8309-f6ece4f50e63>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#a136c8f4-fec1-46e4-8074-863e00fc3fd3>
	rdf:type pr:Epoch ;
	isoC:label "Treatment"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#2948f348-a030-41d4-8136-e4c6f8d786a2>
	rdf:type pr:Arm ;
	isoC:label "High Dose"^^xsd:string ;
	pr:description "High Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#cf260b9d-1b56-4417-bf09-7e828a54ddb4>
	rdf:type pr:Arm ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:description "Low Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#4979e5c0-a517-4f3e-ba9b-53cf5c056788>
	rdf:type pr:Arm ;
	isoC:label "Placebo"^^xsd:string ;
	pr:description "Placebo"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#0952c0bd-36c7-4090-b80e-0033fc03a473>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#2948f348-a030-41d4-8136-e4c6f8d786a2> ;
	pr:inEpoch <http://www.assero.co.uk/EP#d6609ada-cb55-4268-8309-f6ece4f50e63> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#2047939d-88f9-4fd9-a059-74a0f53161f5> ;
.
<http://www.assero.co.uk/ELE#3d1e48a7-5325-4f61-aaeb-a79fd158cd63>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#cf260b9d-1b56-4417-bf09-7e828a54ddb4> ;
	pr:inEpoch <http://www.assero.co.uk/EP#d6609ada-cb55-4268-8309-f6ece4f50e63> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#2047939d-88f9-4fd9-a059-74a0f53161f5> ;
.
<http://www.assero.co.uk/ELE#bc997c10-9c0a-4b34-978e-a5f3713da6b0>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4979e5c0-a517-4f3e-ba9b-53cf5c056788> ;
	pr:inEpoch <http://www.assero.co.uk/EP#d6609ada-cb55-4268-8309-f6ece4f50e63> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#2047939d-88f9-4fd9-a059-74a0f53161f5> ;
.
<http://www.assero.co.uk/ELE#e4976bfe-d9ae-4a66-b6e3-b486345f35d4>
	rdf:type pr:Element ;
	isoC:label "High Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#2948f348-a030-41d4-8136-e4c6f8d786a2> ;
	pr:inEpoch <http://www.assero.co.uk/EP#a136c8f4-fec1-46e4-8074-863e00fc3fd3> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#d0931f3b-ba9d-419c-a404-69092e096beb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#e90243b3-1b0e-4ce8-bf0e-053936369b24> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#181e17f1-f6cc-47ef-8e90-5ccbd854c51c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#14e45894-c12d-4cb8-b6a1-6d8ec81da55f> ;
.
<http://www.assero.co.uk/ELE#6b2eb142-2035-4b11-8d43-1a831b190959>
	rdf:type pr:Element ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#cf260b9d-1b56-4417-bf09-7e828a54ddb4> ;
	pr:inEpoch <http://www.assero.co.uk/EP#a136c8f4-fec1-46e4-8074-863e00fc3fd3> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#d0931f3b-ba9d-419c-a404-69092e096beb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#e90243b3-1b0e-4ce8-bf0e-053936369b24> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#181e17f1-f6cc-47ef-8e90-5ccbd854c51c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#14e45894-c12d-4cb8-b6a1-6d8ec81da55f> ;
.
<http://www.assero.co.uk/ELE#c46647be-f2bf-4dda-97ea-8e67489c11c2>
	rdf:type pr:Element ;
	isoC:label "Placebo"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4979e5c0-a517-4f3e-ba9b-53cf5c056788> ;
	pr:inEpoch <http://www.assero.co.uk/EP#a136c8f4-fec1-46e4-8074-863e00fc3fd3> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#d0931f3b-ba9d-419c-a404-69092e096beb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#e90243b3-1b0e-4ce8-bf0e-053936369b24> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#181e17f1-f6cc-47ef-8e90-5ccbd854c51c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#14e45894-c12d-4cb8-b6a1-6d8ec81da55f> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "LY246708"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:36+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "H2Q-MC-LZZT"^^xsd:string ;
	pr:title "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease."^^xsd:string ;
	pr:shortTitle "LY246708"^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#2948f348-a030-41d4-8136-e4c6f8d786a2> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#cf260b9d-1b56-4417-bf09-7e828a54ddb4> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#4979e5c0-a517-4f3e-ba9b-53cf5c056788> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#d6609ada-cb55-4268-8309-f6ece4f50e63> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#a136c8f4-fec1-46e4-8074-863e00fc3fd3> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#da97e131-852b-4a00-9f4f-3ebbc452cbca> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#e5abbb13-39a5-4bdb-bac5-38d895a1120f> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#cb6188fa-74ba-42ce-884b-70f768f1a0f4> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#31463563-6821-4716-8aba-616be7e1aa78> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "LY246708"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15601> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66735/V4#C66735_C15228> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "DS8500-A-U202"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:36+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "DS8500-A-U202"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_DIA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_M/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "DS8500"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:36+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_RA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_I/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT TALIB RA BWE"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C16084> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "FLU 001"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:36+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "FLU 001"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_INF/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_V/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "FLU001"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15602> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS>
	rdf:type bc:Assessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:36+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "ASS DAD"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105183/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105181/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105171/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105204/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "5"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105199/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "6"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105173/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "7"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105202/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "8"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105203/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "9"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105172/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "10"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105185/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "11"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105178/V1#BCI> ;
.
<http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "BL"^^xsd:string ;
.
<http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123>
	rdf:type pr:Visit ;
	isoC:label "Week 8"^^xsd:string ;
	pr:shortName "Wk8"^^xsd:string ;
.
<http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e>
	rdf:type pr:Visit ;
	isoC:label "Week 12"^^xsd:string ;
	pr:shortName "Wk12"^^xsd:string ;
.
<http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83>
	rdf:type pr:Visit ;
	isoC:label "Week 16"^^xsd:string ;
	pr:shortName "Wk16"^^xsd:string ;
.
<http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292>
	rdf:type pr:Visit ;
	isoC:label "Week 24"^^xsd:string ;
	pr:shortName "Wk24"^^xsd:string ;
.
<http://www.assero.co.uk/TP#2047939d-88f9-4fd9-a059-74a0f53161f5>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#8cf29c5a-1ec0-4ceb-bcdf-de00c47c2f1b> ;
	pr:inVisit <http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#e4600af4-8a6e-4532-ad52-b5ea88b9448e> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#07c1dc16-375c-4658-a54c-ac8e74f64292> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#0962e369-9306-48a8-9a7b-2e3674b2288c> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#adeb1851-2652-4423-aa47-7da0d9a5311a> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#1af47359-5a09-4ddb-b26a-9fcaee5495c3> ;
.
<http://www.assero.co.uk/TP#d0931f3b-ba9d-419c-a404-69092e096beb>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#ce16ed40-4d08-44ea-8cfd-cb148bc45810> ;
	pr:inVisit <http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#3f56e84f-1d8a-4fcb-9c0f-d10ebb59368b> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#2896eea5-dfdd-448b-8fea-6bb677553d73> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#c236db2a-cf67-4502-91a4-a983afbc035f> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#2ca25678-f828-4a52-95cb-d61410032bcd> ;
.
<http://www.assero.co.uk/TP#e90243b3-1b0e-4ce8-bf0e-053936369b24>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#1eeed2c5-9015-4363-af71-a99961e6c81f> ;
	pr:inVisit <http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#cb5d3031-0bac-4ad6-922a-8e18aca7f464> ;
.
<http://www.assero.co.uk/TP#181e17f1-f6cc-47ef-8e90-5ccbd854c51c>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#96d40b08-e73c-4f16-8104-38cc4050169b> ;
	pr:inVisit <http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#e184d09c-954e-4b8d-bb46-4f623f7c3714> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#5d7d74b6-f01b-45a4-be70-b483444cfc62> ;
.
<http://www.assero.co.uk/TP#14e45894-c12d-4cb8-b6a1-6d8ec81da55f>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#0745ff2b-979a-4a99-b5af-a03272106a78> ;
	pr:inVisit <http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#4d74fa64-dccf-4928-b295-ef592eafb768> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#65c826ab-77e1-4433-9319-49df28d87fac> ;
.
<http://www.assero.co.uk/IC#8cf29c5a-1ec0-4ceb-bcdf-de00c47c2f1b>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "0"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#ce16ed40-4d08-44ea-8cfd-cb148bc45810>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4838400"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#1eeed2c5-9015-4363-af71-a99961e6c81f>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "7257600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#96d40b08-e73c-4f16-8104-38cc4050169b>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "9676800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#0745ff2b-979a-4a99-b5af-a03272106a78>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "14515200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#da97e131-852b-4a00-9f4f-3ebbc452cbca>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimer’s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_1/V1#OB> ;
.
<http://www.assero.co.uk/IC#e5abbb13-39a5-4bdb-bac5-38d895a1120f>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_3/V1#OB> ;
.
<http://www.assero.co.uk/IC#cb6188fa-74ba-42ce-884b-70f768f1a0f4>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_4/V1#OB> ;
.
<http://www.assero.co.uk/IC#31463563-6821-4716-8aba-616be7e1aa78>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimer’s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_5/V1#OB> ;
.
<http://www.assero.co.uk/IC#0e23d6da-b1cd-4a75-b6ef-3f6da9faa69c>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_6/V1#OB> ;
.
<http://www.assero.co.uk/IC#6e9452f9-d1f6-40f3-8b0e-f069310d8cac>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimer’s Disease Assessment Scale – Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#d66799c8-4681-40cb-a659-c25b802a4d73>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
.
<http://www.assero.co.uk/IC#13b98c2b-d5b8-46ea-8d75-a484c0daf31d>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#1a75bf73-ccaa-47e8-a221-93e16676a4b6>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
.
<http://www.assero.co.uk/IC#da65bdaf-1643-4568-a1f8-cd654d38975b>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
.
<http://www.assero.co.uk/IC#694706be-9b05-43e9-b5a8-b3e5b2b67ec1>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
.
<http://www.assero.co.uk/IC#3e57347c-c375-43d6-a569-d691842c3b88>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
.
<http://www.assero.co.uk/IC#d719da38-47b7-4878-8a8d-a5977f72cecc>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#d20d17ca-10e4-4d03-9c8c-b39976c9bf67>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
.
<http://www.assero.co.uk/STA#e4600af4-8a6e-4532-ad52-b5ea88b9448e>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STA#3f56e84f-1d8a-4fcb-9c0f-d10ebb59368b>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STFRM#07c1dc16-375c-4658-a54c-ac8e74f64292>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#2896eea5-dfdd-448b-8fea-6bb677553d73>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#e184d09c-954e-4b8d-bb46-4f623f7c3714>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#4d74fa64-dccf-4928-b295-ef592eafb768>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#0962e369-9306-48a8-9a7b-2e3674b2288c>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#c236db2a-cf67-4502-91a4-a983afbc035f>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#5d7d74b6-f01b-45a4-be70-b483444cfc62>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#65c826ab-77e1-4433-9319-49df28d87fac>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#adeb1851-2652-4423-aa47-7da0d9a5311a>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#cb5d3031-0bac-4ad6-922a-8e18aca7f464>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#1af47359-5a09-4ddb-b26a-9fcaee5495c3>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.
<http://www.assero.co.uk/STFRM#2ca25678-f828-4a52-95cb-d61410032bcd>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.